Showing 1421-1430 of 8649 results for "".
- AAVantgarde Bio Announces FDA Fast Track Designation for AAVB-039 for the Treatment of Stargardt Diseasehttps://modernod.com/news/aavantgarde-bio-announces-fda-fast-track-designation-for-aavb-039-for-the-treatment-of-stargardt-disease/2484122/AAVantgarde Bio announced that the US FDA has granted Fast Track Designation for AAVB-039, the company’s gene therapy program for Stargardt disease secondary to biallelic mutation in ABCA4. The Investigational New Drug application for AAVB-039 was cleared to proceed by the FDA. St
- Prevent Blindness Forms New Diabetes + the Eyes Advisory Committeehttps://modernod.com/news/prevent-blindness-forms-new-diabetes-the-eyes-advisory-committee/2482934/Prevent Blindness has created a new Diabetes + the Eyes Advisory Committee. The volunteer panel will guide national initiatives to raise awareness, expand access to care, and improve early detection of diabetes-related eye diseases.
- Myra Vision Secures FDA Approval to Initiate US-Based IDE Study in Glaucomahttps://modernod.com/news/myra-vision-secures-fda-approval-to-initiate-us-based-ide-study-in-glaucoma/2482933/Myra Vision announced today that the FDA has issued a conditional approval letter for its investigational device exemption (IDE) application, allowing the company to initiate the ADAPT study. The prospective, nonr
- VSY Biotechnology Launches Enova Hydrophobic IOLs with Rotaryjet Technologyhttps://modernod.com/news/vsy-biotechnology-launches-enova-hydrophobic-iols-with-rotaryjet-technology/2482932/VSY Biotechnology has launched the Enova Hydrophobic IOLs, with the company's Rotaryjet Preloaded Delivery System. This technology is designed to provide ophthalmic surgeons with a safer, more efficient, and user-friendly solution for lens implantation. The patented Rotary
- Ocular Therapeutix Secures FDA Special Protocol Assessment for NPDR Trial of Axpaxlihttps://modernod.com/news/ocular-therapeutix-secures-fda-special-protocol-assessment-for-npdr-trial-of-axpaxli/2482930/Ocular Therapeutix has received written agreement from the FDA under a Special Protocol Assessment (SPA) for the registrational trial design of Axpaxli (OTX-TKI) for the treatment of nonproliferative diabetic retinopathy (NPDR).
- First FDA-Approved Treatment for MacTel Performed; Dr. Wykoff Shares Experiencehttps://modernod.com/news/first-fda-approved-treatment-for-mactel-performed/2482928/Neurotech Pharmaceuticals announced the first commercial manufacturing, shipment, and surgical procedure for its encapsulated cell-based gene therapy Encelto (revakinagene taroretcel-lwey). Encelto was approved in March 2025 as the first and only FDA
- OKYO Pharma Secures Funding to Advance Urcosimod for Neuropathic Corneal Painhttps://modernod.com/news/okyo-pharma-secures-funding-to-advance-urcosimod-for-neuropathic-corneal-pain/2482926/OKYO Pharma announced it has received $1.9 million in non-dilutive funding to accelerate the clinical development of urcosimod, the company’s lead candidate for treating Neuropathic Corneal Pain (NCP) “Neur
- New Study Links Physical Activity to Slower Glaucoma Progressionhttps://modernod.com/news/new-study-links-physical-activity-to-slower-glaucoma-progression/2482921/A new study has revealed that higher levels of physical activity may significantly slow the progression of visual field loss in individuals with glaucoma. The findings suggest that lifestyle modifications could become an important complement to traditional glaucoma
- Mark Maire Appointed CEO of Rebionhttps://modernod.com/news/mark-maire-appointed-ceo-of-rebion/2482920/Rebion, a provider of neuro-visual diagnostics and digital retinal imaging technologies, announced the appointment of Mark Maire as Chief Executive Officer. Mr. Maire brings more than two decades of commercial leadership and strategic growth experience, including the sale of TrueVi
- Alcon to Acquire Staar Surgical for $1.5 Billionhttps://modernod.com/news/alcon-to-acquire-staar-surgical-for-15-billion/2482917/In a major deal to expand its refractive portfolio and continue its spree of acquisitions, Alcon has agreed to acquire Staar Surgical, maker of the Implantable Collamer Lens (ICL). The acquisition includes the EVO family of l